First Tracks Biotherapeutics (TRAX) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zymeworks is the larger company by market cap ($1.81 billion vs $1.75 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRAX | ZYME |
|---|---|---|
| Share price | $41.64 | $26.14 |
| Market cap | $1.75B | $1.81B |
| 1-day change | -6.34% | -2.68% |
| YTD return | — | -0.72% |
| 1-year return | — | +8.83% |
| 5-year return | — | +34.05% |
| P/E ratio (TTM) | — | 49.32 |
| Forward P/E | — | 54.95 |
| EPS (TTM) | $-4.71 | $0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $105.97M |
| Revenue growth (YoY) | — | +38.87% |
| Net income (latest FY) | — | $-81.13M |
| Operating margin | — | -87.34% |
| Net margin | — | -76.56% |
| 52-week high | $54.78 | $31.97 |
| 52-week low | $14.72 | $21.52 |
| Distance from 52-week high | -23.99% | -18.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +80.52% | +65.61% |
| Average volume | 826.70K | 1.09M |
| Shares outstanding | 42.02M | 68.70M |
| Employees | 104 | 279 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About First Tracks Biotherapeutics
TRAX stock →First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 104 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees
TRAX vs ZYME FAQ
Which is bigger, First Tracks Biotherapeutics or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.81B compared with $1.75B for First Tracks Biotherapeutics (TRAX).
Are First Tracks Biotherapeutics and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.